Apimeds Pharmaceuticals US, Inc. (APUS)
4.55
-0.07
(-1.52%)
USD |
NYAM |
Oct 14, 10:54
Apimeds Pharmaceuticals US Total Liabilities (Quarterly) : 21.18M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 21.18M |
| March 31, 2026 | 14.70M |
| December 31, 2025 | 10.84M |
| September 30, 2025 | 1.089M |
| June 30, 2025 | 0.809M |
| March 31, 2025 | 2.020M |
| Date | Value |
|---|---|
| December 31, 2024 | 1.371M |
| September 30, 2024 | 1.083M |
| June 30, 2024 | 0.7876M |
| March 31, 2024 | 0.4223M |
| December 31, 2023 | 0.3902M |
| September 30, 2023 | 0.7771M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 127.62M |
| Shareholders Equity (Quarterly) | 106.45M |
| Debt to Equity Ratio | 0.1369 |
| Current Ratio | 0.5067 |
| Net Debt Paydown Yield | -20.17% |